Immunotherapy

Immunotherapy

The combination cohort consisted of 119 patients who received nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by nivolu­mab 3 mg/kg every 2 weeks. The median follow-up was 13.4 months.

“We find that T-cells with highly activated glycolysis pathways ended up performing worse when we tried to make them into CAR T-Cells. Substituting and supplementing heavily with fatty acids did seem to improve this a little,” said David M. Barrett, MD, PhD, at the 2018 American Association for Cancer Research annual meeting.

“The main rationale from the cytotoxic era is to increase efficacy by combining agents that have different mechanisms and nonoverlapping toxicities. The question is whether we can replace nonspecific cytotoxic agents with a specific, more effective immunotherapeutic,” said Donna Przepiorka, MD, PhD, at ASH 2017.

Chicago, IL—The tumor types amenable to immunotherapy with the PD-1 inhibitor pembrolizumab (Keytruda) keep expanding and now include sarcoma, which has been difficult to treat.
The power to fight a virtually infinite array of pathogens is one of the hallmarks of the human immune system, and random diversity is its secret weapon.
Adding the investigational drug indoximod, an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor, to the checkpoint inhibitor pembrolizumab led to higher response rates in patients with advanced melanoma than what is reported with pembrolizumab monotherapy,
Despite remarkable advancements in the treatment of cancer through the use of targeted agents and immunotherapy, outcomes are still varied, and, for some patients, these regimens provide only a short-term answer.
The advent of immunotherapy has led to durable clinical responses in a variety of malignancies, but identifying which patients will respond to treatment remains elusive.
The relative lack of progress in the treatment of malignant pleural mesothelioma is in marked contrast to developments in the treat­ment of lung cancer overall, but several ongoing studies using different immune-based therapies have shown promise in the treatment of this type of cancer.
Response is a poor outcome measure of immunotherapy, according to Tanguy Seiwert, MD, who addressed this and other concerning issues in immunotherapy at the 2016 Multidisciplinary Head and Neck Cancer Symposium.
Page 2 of 3
Results 11 - 20 of 26